As evident, Hazlitt’s one lesson has vast applications. This essay now delves into its deployment on the Danish welfare state ...

NEW YORK, NY / ACCESS Newswire / March 17, 2025 / Bernstein Liebhard LLP:Do you, or did you, own shares of Novo Nordisk A/S (NYSE:NVO)?Did you ...

Novo Nordisk announced that its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes lose 15.7% of their weight in a recent trial. That figure ...

Shares of Novo Nordisk slipped in Monday morning trading after the company announced results of its latest weight-loss drug trial. Novo's results from its Redefine 2 late-stage trial of ...

Shares of Novo Nordisk fell on Monday, after the Danish pharmaceutical giant said its next-generation weight-loss drug CagriSema helped obese or overweight adult patients with type 2 diabetes drop ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

Novo Nordisk is rolling out a new national marketing campaign for its GLP-1 juggernaut, teaming up with celebrities and other patients to show what life looks like in their “Ozempic Eras.” ...

Novo Nordisk (NYSE: NVO) stock ran up 3.5% through 10:05 a.m. ET Friday morning on some good news for it (and for Eli Lilly) that's also probably bad news for Hims & Hers Health (NYSE: HIMS).

Even with the shortage, Novo Nordisk saw fourth-quarter Wegovy sales more than double to 19.9 billion Danish kroner ($2.9 billion), and full-year 2024 sales jumped 25% to $40.6 billion, driven by ...

Novo Nordisk (NVO) shares stumble after the results of the drugmaker's weight loss drug trial showed that patients using the drug dropped only around 15% of their weight, compared to the 25% that ...